주사기 시장 : 유형, 소재, 기술, 수량, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Syringes Market is projected to grow by USD 24.06 billion at a CAGR of 7.98% by 2032.

Syringes Market Introduction

The syringes market is a mission-critical segment of medical devices, supporting vaccination, diabetes care, injectable biologics, anesthesia, emergency medicine, and hospital drug delivery. Demand is anchored by verified healthcare fundamentals: the World Health Organization estimates that approximately 16 billion injections are administered worldwide each year, while chronic disease management and immunization programs continue to raise the need for sterile, accurate, and safe injection devices.

Market relevance is shifting from commodity disposable syringes toward safety syringes, auto-disable syringes, insulin syringes, low-dead-space syringes, and prefilled syringe systems that reduce medication errors, needle-stick injuries, reuse risk, and contamination. Regulatory expectations under FDA quality system requirements, EU Medical Device Regulation, ISO 7886, ISO 8537, and WHO performance and prequalification guidance are making product reliability, traceability, sterility assurance, and supply resilience central buying criteria for healthcare providers, pharmaceutical manufacturers, and public procurement agencies.

Transformative Shifts in the Syringes Landscape

The syringes landscape is being reshaped by three durable shifts: safer injection practice, growth in self-administration, and higher scrutiny of device quality. Safety-engineered syringes are supported by OSHA bloodborne pathogen requirements in the United States and the EU Sharps Directive, while auto-disable syringes remain essential in mass immunization because they help prevent reuse and support WHO-aligned injection safety practices.

At the same time, injectable biologics, insulin therapy, GLP-1 medications, anticoagulants, fertility treatments, and home-based care are increasing demand for user-friendly delivery formats. Hospitals, pharmaceutical companies, and contract manufacturers are also prioritizing low-dead-space designs, latex-free components, consistent plunger performance, container-closure integrity, extractables and leachables control, and compatibility with high-value drugs, making syringe selection a clinical, regulatory, and supply-chain decision rather than a price-only purchase.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing the syringe value chain, from automated visual inspection to predictive maintenance on molding, siliconization, needle assembly, packaging, and sterilization-related production workflows. AI-enabled computer vision can help identify particulate contamination, cosmetic defects, dimensional inconsistencies, fill-level deviations, needle alignment issues, and labeling errors at speeds that support high-volume sterile manufacturing.

The cumulative impact is stronger quality assurance and lower batch risk, especially for prefilled syringes, safety syringe mechanisms, and insulin syringe components where tolerance failures can affect dose accuracy, sterility, activation, or user safety. AI is also improving demand planning for vaccination campaigns, hospital formularies, emergency stockpiles, and chronic therapy segments, helping manufacturers and procurers align capacity with public-health requirements while reducing stockouts, excess inventory, and avoidable supply disruption.

Key Regional Insights

Asia-Pacific is a major production and demand center for syringes, supported by large immunization programs, expanding diabetes prevalence, population scale, and strong device manufacturing bases in China, India, Japan, South Korea, and Australia. The region's syringe demand is reinforced by public vaccination, hospital expansion, injectable pharmaceuticals, and growing use of precision delivery devices in advanced healthcare systems. North America remains a high-value syringe market because of strong safety syringe adoption, chronic injectable therapies, FDA oversight, OSHA-driven sharps safety practices, large hospital purchasing networks, and established demand for prefilled syringe systems used with biologics and specialty drugs.

Latin America is driven by public vaccination, hospital modernization, private clinic expansion, and broader access to injectable treatments, with Brazil and Mexico serving as important demand anchors. Europe is shaped by the EU Medical Device Regulation, high sharps safety standards, strong post-market surveillance expectations, and established uptake of prefilled, safety, and specialty syringes across hospital and self-administration settings. The Middle East is investing in hospital infrastructure, emergency care capacity, and medical localization, particularly in GCC countries where procurement quality and sterile supply reliability are rising priorities. Africa's syringe demand is closely linked to donor-supported immunization, maternal health, infectious disease programs, primary care access, and the need for WHO-aligned auto-disable syringes that support safe injection practices in high-volume public-health campaigns.

Key Group Insights

ASEAN benefits from rising healthcare access, expanding hospital networks, medical tourism, and regional manufacturing capacity, making it important for both standard disposable syringes and higher-value safety products. The GCC is accelerating hospital investment, procurement modernization, and healthcare localization, supporting demand for premium sterile devices, emergency-care supplies, vaccine delivery products, and reliable syringe supply chains aligned with public-sector quality requirements.

The European Union emphasizes MDR compliance, sharps safety, traceability, clinical evidence, and sustainable procurement, which favors suppliers with strong technical documentation, quality systems, and post-market surveillance. BRICS countries combine large patient populations with expanding domestic manufacturing ambitions, particularly in China, India, and Brazil, where immunization scale, diabetes care, and pharmaceutical production increase syringe relevance. G7 markets concentrate advanced demand for prefilled syringes, biologic compatibility, safety-engineered devices, and low-defect manufacturing, while NATO countries' medical readiness priorities reinforce the importance of resilient syringe supply for defense health systems, emergency preparedness, field medicine, and public-health response.

Key Country Insights

The United States leads in safety-engineered devices, injectable therapies, prefilled syringe adoption, and FDA-driven quality expectations, while Canada emphasizes universal healthcare procurement, safe injection standards, and reliable access across hospital and community care settings. Mexico and Brazil are important Latin American syringe markets due to public immunization, hospital demand, chronic disease care, and growing local distribution networks that support broader access to sterile injection devices.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show strong demand for compliant safety syringes, insulin syringes, and prefilled systems, with procurement influenced by sharps safety, MDR-aligned quality expectations, and hospital efficiency. Russia's market is shaped by domestic supply needs, localization priorities, and healthcare self-sufficiency. China and India are central to global syringe production and domestic immunization scale, with China facing heightened international quality scrutiny and India benefiting from vaccine, pharmaceutical, and medical device manufacturing depth. Japan, Australia, and South Korea emphasize high-quality precision devices, aging-population care, regulated procurement, and consistent performance in hospital, home-care, and specialty injectable therapy settings.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize product portfolios that combine safety, dose accuracy, usability, and regulatory resilience. Investments in ISO-compliant design controls, supplier qualification, sterilization validation, biocompatibility assessment, container-closure integrity, and lot-level traceability are essential as health systems demand proof of performance and as regulators increase scrutiny of syringe defects, leakage, particulate contamination, labeling accuracy, and drug-device compatibility risks.

Manufacturers should expand capabilities in safety syringes, auto-disable syringes, insulin delivery, low-dead-space designs, and prefilled-compatible platforms while diversifying raw material, needle, elastomer, barrel, and packaging component sourcing. Commercial teams should align messaging with measurable outcomes: reduced needle-stick injury risk, lower medication waste, reliable immunization delivery, improved patient adherence in home-care settings, and stronger continuity of supply for hospitals, public-health agencies, and pharmaceutical partners.

Research Methodology

This executive summary is based on secondary research from recognized public-health, regulatory, and standards sources, including WHO injection safety guidance, UNICEF immunization supply references, FDA medical device communications, OSHA bloodborne pathogen requirements, the EU Sharps Directive, EU MDR requirements, and ISO syringe standards such as ISO 7886 and ISO 8537.

The analysis also applies market triangulation across clinical-use trends, procurement behavior, chronic disease demand, vaccination programs, device manufacturing practices, quality-system requirements, and regional healthcare infrastructure. Insights were validated for consistency with documented regulatory frameworks, public-health guidance, standards-based performance expectations, and observable demand drivers rather than unverified market-size, market-share, or forecasting claims.

Conclusion

The syringes market is evolving from a high-volume consumable category into a strategically important medical device sector shaped by safety, precision, regulatory compliance, sterility assurance, and resilient supply chains. Demand is supported by immunization needs, chronic disease care, injectable biologics, hospital procedures, emergency medicine, and expanding home administration.

Organizations that combine dependable manufacturing, advanced quality controls, AI-enabled inspection, validated sterilization, strong documentation, and region-specific regulatory execution will be best positioned to support hospital, public-health, and pharmaceutical partnerships in the next phase of syringe market development.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Syringes Market, by Type

• 7.1. Disposable
• 7.2. Reusable

8. Syringes Market, by Material

• 8.1. Glass
• 8.2. Plastic
• 8.3. Stainless Steel

9. Syringes Market, by Technology

• 9.1. Prefill
  • 9.1.1. Auto Injector
  • 9.1.2. Cartridge
• 9.2. Safety
  • 9.2.1. Active
  • 9.2.2. Passive
• 9.3. Smart
• 9.4. Standard

10. Syringes Market, by Volume

• 10.1. High Volume
• 10.2. Low Volume
• 10.3. Medium Volume

11. Syringes Market, by End User

• 11.1. Hospitals & Clinics
• 11.2. Diagnostic Centers
• 11.3. Blood Banks
• 11.4. Pharmaceutical & Biotech Companies

12. Syringes Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Syringes Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Syringes Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. B. Braun Melsungen AG
• 16.2. Baxter International Inc.
• 16.3. Becton, Dickinson and Company
• 16.4. Cardinal Health, Inc.
• 16.5. Catalent, Inc.
• 16.6. Codan Medizinische Gerate GmbH & Co. KG
• 16.7. Dispomed Witt oHG
• 16.8. Gerresheimer AG
• 16.9. Grand River Aseptic Manufacturing, Inc
• 16.10. Henke-Sass, Wolf GmbH
• 16.11. KDL Biotech Limited
• 16.12. Medtronic plc
• 16.13. Nipro Corporation
• 16.14. Owen Mumford Limited
• 16.15. Poly Medicure Limited
• 16.16. Retractable Technologies, Inc.
• 16.17. Schott AG
• 16.18. Shandong Weigao Group Medical Polymer Co., Ltd.
• 16.19. SHL Medical AG
• 16.20. Stevanato Group S.p.A.
• 16.21. Terumo Corporation
• 16.22. Unilife Corporation
• 16.23. Vetter Pharma-Fertigung GmbH & Co. KG
• 16.24. Weigao Group Medical Polymer Company Limited
• 16.25. West Pharmaceutical Services, Inc.
• 16.26. Ypsomed Holding AG